TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02463448

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Muscle Derived Cells
Description: A small sample of the subject's own thigh muscle is obtained by needle biopsy. The biopsy sample is sent to Cook Myosite, Inc. for growth and processing. When the sample cell dosage is achieved the cells are frozen and sent back to the treatment site. The cells are thawed, diluted and injected under lighted instrumentation and visualization into about 30 sites in the bladder wall.
Study: NCT02545634

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. helveticus R0052 and B. longum R0175
Description: See arm descriptions for intervention description.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04678375

Intervention type: DIAGNOSTIC_TEST
Intervention: Retinal diseases diagnosed by artificial intelligence algorithm
Description: An artificial intelligence algorithm was applied to diagnose referral diabetes retinopathy, referral age-related macular degeneration, referral possible glaucoma, pathological myopia, retinal vein occlusion, macular hole, macular epiretinal membrane, hypertensive retinopathy, myelinated fibers, retinitis pigmentosa and other retinal lesions from fundus photography.
Study: NCT01152398

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-HER2
Description: experimental vaccine, subcutaneous injection q4weeks x6
Study: NCT02670109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: 300mg/m2, IV, in 3 hours, during day -4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 80mg/kg, IV, in 2 hours, during two days -2, -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 1400/m2, IV, in 1 hour, during day -3
Study: NCT04039698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velpatasvir/Sofosbuvir
Description: Velpatasvir 100mg / Sofosbuvir 400mg once a day for twelve weeks
Study: NCT02670109

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Transfusion, in 3 hours, during day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 16mg/kg, Oral, during day -4
Study: NCT03484910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Description: Six-week training program of stationary cycling with / without a real-time visual EMG biofeedback

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise therapy
Description: Six-week training program of stationary cycling with / without a real-time visual EMG biofeedback
Study: NCT02446340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalazatide
Description: Different doses of drug, subcutaneous injection twice per week for a total of 9 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalazatide
Description: Different doses of drug, subcutaneous injection twice per week for a total of 9 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalazatide
Description: Different doses of drug, subcutaneous injection twice per week for a total of 9 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalazatide
Description: Different doses of drug, subcutaneous injection twice per week for a total of 9 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo delivered via subcutaneous administration twice per week for a total of 9 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo delivered via subcutaneous administration twice per week for a total of 9 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo delivered via subcutaneous administration twice per week for a total of 9 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo delivered via subcutaneous administration twice per week for a total of 9 doses
Study: NCT03973034

Intervention type: DIAGNOSTIC_TEST
Intervention: Low depth whole genome sequencing
Description: Low depth whole genome sequencing of the peripheral blood samples from different groups.

Intervention type: DIAGNOSTIC_TEST
Intervention: Low depth whole genome sequencing
Description: Low depth whole genome sequencing of the peripheral blood samples from different groups.

Intervention type: DIAGNOSTIC_TEST
Intervention: Low depth whole genome sequencing
Description: Low depth whole genome sequencing of the peripheral blood samples from different groups.
Study: NCT03640299

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS procedure
Description: Optimized preoperative, intraoperative and postoperative procedures.
Study: NCT02006758

Intervention type: DEVICE
Intervention: EnligHTN™ Renal Denervation System
Description: The EnligHTN™ Renal Denervation System is designed to deliver radiofrequency (RF) energy to the renal nerves to achieve targeted denervation. The system consists of the EnligHTN™ RF Ablation Generator (generator), the EnligHTN™ Renal Artery Ablation Catheter (ablation catheter), and the EnligHTN™ Guiding Catheter (optional).
Study: NCT00409838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Intravenous (IV) solution, - weight tiered (500 mg \<60 kg); (750 mg 60-100 kg); (1 gram \> 100 kg), Day 1, Day 15, Day 29; every 28 days thereafter, 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Tablets, Oral, ≥ 15 mg, weekly, 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Tablets, Oral, ≥ 15 mg, weekly, 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV solution, Intravenous, D5W, Day 1, Day 15, Day 29; every 28 days thereafter, 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Solution, intravenous, 10 mg/kg, every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Tablets, oral, 15 mg weekly to be adjusted according to patient condition
Study: NCT03177824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil Citrate 25Mg Tab
Description: Group 1, consists of 30 patients who will receive Sildenafil citrate (25mg) tab (Silden, Epico, Egypt) 3times daily till the time of delivery, followed by repeating the Doppler US scan serially to detect changes in the measured indices and then assess the neonatal outcome after delivery as regard birth weight and APGAR score.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Group 2, consists of 30 patients receiving placebo Oral Tablet 3times daily , followed by repeating the Doppler US scan serially to detect changes in the measured indices and then assess the neonatal outcome after delivery as regard birth weight and APGAR score
Study: NCT02847715

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ePRIME
Description: ePRIME is an remote monitoring pathway that includes an online system for patients to self-report symptoms and AE following cancer treatments. ePRIME allows AE reporting from home and enables patient reported data to be integrated into existing EPR to allow for the reports to be used in routine care. In addition the system is capable of generating alerts for serious symptoms to the relevant clinical team and providing patient advice on managing mild and moderate symptoms.
Study: NCT02611609

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MultiStem

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MultiStem

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MultiStem

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01433315

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sleep restriction
Description: restricted sleep
Study: NCT01057433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin (NK-104)
Description: pitavastatin (NK-104) 4 mg once daily (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: lopinavir/ritonavir 800 mg/200 mg
Study: NCT03014518

Intervention type: OTHER
Intervention: Clinical assessments and blood samples; follow-up for 12 mos
Description: Kiddie-Sads Present and Lifetime Version Diagnostic Interview, Columbia-Suicide Severity Rating Scale, Suicidal Ideation Questionnaire, Children's Depression Rating Scale-Revised, Multidimensional Anxiety Scale for Children (2nd Ed), Adverse Childhood Experiences Questionnaire, Life Events Checklist-5, Pubertal Development Scale. All assessments administered at baseline, and a smaller subset of assessments administered at discharge and other time points throughout 12 months follow-up. Blood samples taken at baseline (admission to unit) and day of discharge.

Intervention type: OTHER
Intervention: Clinical assessments and blood samples; no 12mo follow-up
Description: Kiddie-Sads Present and Lifetime Version Diagnostic Interview, Columbia-Suicide Severity Rating Scale, Suicidal Ideation Questionnaire, Children's Depression Rating Scale-Revised, Multidimensional Anxiety Scale for Children (2nd Ed), Adverse Childhood Experiences Questionnaire, Life Events Checklist-5, Pubertal Development Scale. All assessments administered at baseline, and a smaller subset of assessments administered at discharge time point (5-7 days after baseline). Blood samples taken at baseline and discharge time points (5-7 days after baseline).
Study: NCT02320370

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroConn DC Stimulator Plus tDCS
Description: transcranial electrical stimulation intervention with two experimental protocols
Study: NCT03053401

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor Canal Block
Description: Under guidance of a linear ultrasound transducer probe (General Electric; GE). Performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg ( maximum of 40 mg ).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block
Description: Under guidance of a linear ultrasound transducer probe (General Electric;GE).Block will be performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg (maximum of 40 mg ).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Use of linear ultrasound transducer probe (General Electric;GE) to guide needle placement for both Adductor Canal Block and Femoral nerve Blocks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Use of linear ultrasound transducer probe (General Electric;GE) to guide needle placement for both Adductor Canal Block and Femoral nerve Blocks
Study: NCT01344278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling
Description: A lifestyle curriculum of individualized telephone counseling calls, augmented with e-mails and an interactive study Web site.
Study: NCT00635232

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irbesartan
Description: 300 mg (2 x 150 mg capsules) once daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsules once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS433540
Description: 200 mg (2 x 100 mg capsules) once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS433540
Description: 400 mg (4 x 100 mg capsules) once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS433540
Description: 800 mg (8 x 100 mg capsules) once daily for 12 weeks
Study: NCT03558178

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Doin with acupuncture
Description: Doin (conduction exercise) will be performed with the needles in situ by increasing the cervical range of motion (rotation) with physician guidance and isometric resistance exercise as indicated. Doin sessions will be conducted 2 times a week for 5 weeks (total 10 sessions).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture will be performed with manual stimulation (needle twirling) to evoke de-qi sensation. Acupuncture sessions will be conducted 2 times a week for 5 weeks (total 10 sessions).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture will be performed with manual stimulation (needle twirling) to evoke de-qi sensation. Acupuncture sessions will be conducted 2 times a week for 5 weeks (total 10 sessions).
Study: NCT01184300

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers
Description: Patients found to carry the CYP2C19\*2 allele will receive prasugrel 10 mg daily for 1 week. Non-carriers will receive clopidogrel 75 mg daily.
Study: NCT02385513

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 10-valent pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 10-valent pneumococcal conjugate vaccine
Study: NCT00810238

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C-Cure
Description: Intraventricular injection
Study: NCT01818232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-LX4211
Study: NCT00680706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiamine
Description: Thiamine (100 mg) in 50 ml D5W, x 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: D5W (50 ml)
Study: NCT01172431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indapamide
Description: Indapamide SR 1.5mg qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide 25mg qd
Study: NCT01866930

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Lambda-1a

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Lambda-1a

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV)
Study: NCT06016036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAL-0951
Description: SAL-0951：~1. initial phase：4mg QD for 8 weeks~2. subsequent phase：1mg、2mg、4mg、6mg、8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SAL-0951 placebo：~1. initial phase：4mg QD for 8 weeks~2. subsequent phase：1mg、2mg、4mg、6mg、8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
Study: NCT01866930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribasphere (RBV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribasphere (RBV)
Study: NCT02967835

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-psychiatry consult
Description: tele-psychiatry consult for evaluation and treatment recommendations
Study: NCT04725461

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low cost lower limb prosthetic socket
Description: A pre-made 3D printed cylinder used as an outer shell is selected for each subject based on their measurements. The space between the residual limb and the outer shell will be filled with an expanding polyurethane foam (Foam IT 8, Smooth On Inc.) that conforms to the residual limb and bonds with the outer shell to form a strong and lightweight socket. The foam forms a smooth surface against the protective sheath; the socket is fully formed once the foam has hardened to the 3D printed cylinder.~A prefabricated supracondylar suspension cuff made of Dacron or nylon, or a commercially available suspension sleeve may be will be applied to the prosthetic socket to aid in suspension. Commercially available components, including the International Committee of the Red Cross (ICRC) transtibial polypropylene component system will be attached to the bottom of the socket to allow the patient to ambulate in the prosthesis.
Study: NCT04051073

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Continuous non-invasive blood pressure monitoring
Description: Continuous non-invasive blood pressure monitoring using CNAP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous non-invasive blood pressure monitoring
Description: Continuous non-invasive blood pressure monitoring using CNAP
Study: NCT00775294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Healthy male volunteers will take maraviroc 300 mg orally twice daily for 15 doses (8 days)
Study: NCT00205179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novasoy
Description: 100mg/day soy isoflavones
Study: NCT01405742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rF.VIII
Description: 40 IU/kg recombinant factor VIII will be given once-weekly or thrice-weekly by intravenous injection for 26 weeks. At 26 weeks after a 72 hour washout period, 40 IU/kg recombinant factor VIII will be given thrice-weekly or once-weekly, respectively, by intravenous injection until week 52, with up to two rescue doses per week for bleeds
Study: NCT00205179

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100mg/day matching placebo
Study: NCT00471328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib
Description: Nilotinib 400 mg twice daily (bid)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib 400 mg twice daily (bid)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Supportive Care (BSC) +/- imatinib or sunitinib
Description: Can include pain medication, localized radiotherapy, nutritional support, and/or oxygen therapy and blood transfusions. Imatinib or sunitinib can be administered at the last tolerated dose and regimen or at the Investigator's choice.
Study: NCT02854631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selonsertib
Description: 18 mg tablet administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone
Description: 40 mg (4 x 10 mg tablets) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: 40 mg (4 x 10 mg tablets) administered orally once daily
Study: NCT02586090

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parents as Coaches
Description: PAC (modeled after NIH-funded NOURISH) focuses on parenting strategies to support and facilitate their child's weight management via family-based change. Each visit includes group psychoeducation and discussion, focused on parenting strategies to facilitate healthy weight management in their child(ren). Topics include focus such as role modeling, strategies for healthy lifestyle changes, and how to be a coach to your teen.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Weight Loss
Description: In PWL parents will be given a weight loss goal of 1-2 lbs/week, as well as specific calorie and fat prescriptions, PA goals, and instructions to self-monitor key information. Parents will receive training in core behavioral weight loss strategies (e.g., goal setting, stimulus control) and techniques to help them achieve these goals and will also receive personalized feedback throughout the program
Study: NCT02247375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose of BIIL 284 BS tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of BIIL 284 BS tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02755259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03741049

Intervention type: DEVICE
Intervention: Scalpel Bougie technique (plastic laryngeal model)
Description: ScalpelBougie Set

Intervention type: DEVICE
Intervention: Scalpel Bougie technique (plastic laryngeal model)
Description: ScalpelBougie Set

Intervention type: DEVICE
Intervention: Scalpel Bougie technique (plastic laryngeal model)
Description: ScalpelBougie Set

Intervention type: DEVICE
Intervention: Scalpel Bougie technique (plastic laryngeal model)
Description: ScalpelBougie Set

Intervention type: DEVICE
Intervention: Seldinger technique (plastic laryngeal model)
Description: Melker Set

Intervention type: DEVICE
Intervention: Seldinger technique (plastic laryngeal model)
Description: Melker Set

Intervention type: DEVICE
Intervention: Seldinger technique (plastic laryngeal model)
Description: Melker Set
Study: NCT03053401

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stimuplex A needle
Description: 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany) used to perform both Adductor Canal Block and Femoral nerve Blocks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stimuplex A needle
Description: 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany) used to perform both Adductor Canal Block and Femoral nerve Blocks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local anaesthetic injection
Description: Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) for either Adductor Canal Block and Femoral nerve Blocks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local anaesthetic injection
Description: Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) for either Adductor Canal Block and Femoral nerve Blocks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid Drug
Description: Methylprednisolone acetate 1 mg/kg (maximum of 40 mg ) for either Adductor Canal Block and Femoral nerve Blocks.
Study: NCT04830059

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Two types of exercise intervention and control group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Two types of exercise intervention and control group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Two types of exercise intervention and control group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Two types of exercise intervention and control group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Two types of exercise intervention and control group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Two types of exercise intervention and control group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Air purification
Description: Air purification in order to reduce the PM2.5 and PM10

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Air purification
Description: Air purification in order to reduce the PM2.5 and PM10